Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Clinical Colorectal Cancer|July 8, 2020
Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER TrialMaria Carmela Piccirillo, Antonio Avallone, Chiara Carlomagno, et al.
International Journal of Cancer|July 1, 2023
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trialStefania Napolitano, Davide Ciardiello, Vincenzo De Falco, et al.
JAMA Network Open|July 26, 2021
Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical TrialAntonio Avallone, Maria C Piccirillo, Guglielmo Nasti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2024
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: The IMPROVE TrialAntonio Avallone, Francesco Giuliani, Alfonso De Stefano, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patientsUmberto Malapelle, Francesco Passiglia, Chiara Cremolini, et al.
JAMA Oncology|May 18, 2023
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialStefania Napolitano, Vincenzo De Falco, Giulia Martini, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2021
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trialGerardo Rosati, Sara Lonardi, Fabio Galli, et al.
Therapeutic Advances in Medical Oncology|August 28, 2020
Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with <i>RAS</i>-mutated metastatic colorectal cancer: the REVOLUTION study protocolAntonio Avallone, Maria Carmela Piccirillo, Elena Di Gennaro, et al.
BMC Cancer|September 11, 2019
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocolAlessandro Ottaiano, Stefania Scala, Nicola Normanno, et al.
Therapeutic Advances in Medical Oncology|April 15, 2021
Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocolAlessandro Ottaiano, Stefania Scala, Mariachiara Santorsola, et al.
Pageof 8